因工作安排原因，陆文超先生不再担任公司总裁职务，董事会授 权董事长在总裁空缺期间代为履行总裁职责。 公司董事会对议案的审议、表决程序合法。 2、任职资格合法 经审阅徐辉先生、林国龙先生个人履历，未发现有《公司法》及 公司《章程》中规定禁止任职的情形及被中国证监会处以证券市场禁 入处罚的情况。经考察，徐辉先生、林国龙先生具备公司董事任职资 格。 独立董事：刘宁、孙茂竹、Zheng Wei、康彩练 2023 年 9 月 21 日 华润双鹤药业股份有限公司独立董事 关于第九届董事会第三十一次会议审议有关事项的独立意见 根据《上市公司独立董事管理办法》《上市公司治理准则》《上 海证券交易所股票上市规则》和公司《章程》的有关规定，我们作为 华润双鹤药业股份有限公司(以下简称"公司")的独立董事，对公司 第九届董事会第三十一次会议审议的《关于变更总裁的议案》《关于 增补董事的议案》进行了审查，发表意见如下： 1、程序合法 公司控股股东在征得徐辉先生、林国龙先生同意后，提名其为公 司第九届董事会董事候选人。 ...

第九届董事会第三十一次会议 2023 年 9 月 21 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2023－062 华润双鹤药业股份有限公司 关于选举董事长及变更总裁的公告 华润双鹤药业股份有限公司(以下简称"公司")于 2023 年 9 月 21 日召开公司第九届董事会第三十一次会议(以下简称"本次会议")。 本次会议审议通过了《关于选举董事长的议案》《关于变更总裁的议 案》，同意选举陆文超先生为公司第九届董事会董事长，授权董事长 在总裁空缺期间代为履行总裁职责。具体情况如下： 因工作安排原因，陆文超先生不再担任公司总裁职务。董事会对 陆文超先生任公司总裁期间的工作表示感谢！ 董事会授权董事长在总裁空缺期间代为履行总裁职责，起止日期 自本议案审批通过之日起，至新任总裁就任之日止。 后续公司将及时办理相关工商变更登记手续。 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 一、选举董事长 董事会经全体董事的过半数选举陆文超先生为公司第九届董事 会董事长，其任职自本次董事会审议批准之日起，至第九届董事会届 满 ...

证券代码：600062 证券简称：华润双鹤 公告编号：2023-063 华润双鹤药业股份有限公司 关于召开 2023 年第四次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 股东大会召开日期：2023年10月9日 本次股东大会采用的网络投票系统：上海证券交易所股东大会 网络投票系统 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第四次临时股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和 网络投票相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2023 年 10 月 9 日 10 点 00 分 召开地点：北京市朝阳区望京利泽东二路 1 号公司会议室 至 2023 年 10 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2023－060 华润双鹤药业股份有限公司 关于回购专用证券账户剩余股份注销完成 暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担法律责任。 重要内容提示： 注销原因：华润双鹤药业股份有限公司(以下简称"公司")第九 届董事会第二十九次会议及 2023 年第三次临时股东大会审议通过了 本次调整公司回购专用证券账户股份用途并注销的事项。 本次注销股份的有关情况 | 回购账户股份剩余数量(股) | 注销股份数量(股) | 注销日期 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 3,386,809 | 3,386,809 | 年 2023 | 9 | 月 | 18 | 日 | 本 次 注销 完成 后， 公 司总 股本 由 1,043,126,810 股 变更 为 1,039,740,001 股。 销。具体内容详见公司分别于 2023 年 7 月 15 日、2023 年 8 月 1 日披 露的《关于调整公 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥5,234,148,011.36, an increase of 6.58% compared to ¥4,910,824,498.76 in the same period last year[18]. - Net profit attributable to shareholders of the listed company was ¥776,799,645.42, reflecting a growth of 5.45% from ¥736,636,737.30 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was ¥722,372,024.58, up by 4.40% from ¥691,905,809.78 year-on-year[18]. - The net cash flow from operating activities was ¥651,972,804.93, showing a decrease of 2.40% compared to ¥668,019,806.97 in the same period last year[18]. - The total assets at the end of the reporting period amounted to ¥15,126,705,942.34, an increase of 4.45% from ¥14,482,536,656.83 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company were ¥10,531,770,707.50, which is a 5.08% increase from ¥10,022,611,149.67 at the end of the previous year[18]. - Basic earnings per share for the first half of 2023 were ¥0.7554, up 5.52% from ¥0.7159 in the same period last year[19]. - The weighted average return on net assets increased to 7.49%, up by 0.23 percentage points from 7.26% in the previous year[19]. Industry Outlook - The pharmaceutical industry in China is expected to maintain an optimistic growth outlook, with an estimated annual growth rate of 4%-5% in 2023[23]. - In the first half of 2023, the industrial economy showed a recovery trend, with a year-on-year increase of 3.8% in the added value of industrial enterprises above designated size[23]. - The global pharmaceutical supply chain is shifting towards China and India, with an expected increase in the growth rate of the raw material drug market[23]. - The aging population and increasing life expectancy are driving significant clinical demand in the healthcare sector[23]. Product Development and Innovation - The new drug approval process has accelerated, with 20 new drugs approved in the first half of 2023, focusing on oncology and rare diseases[23]. - The company has established 2 innovative technology platforms focused on antiviral and anti-tumor projects, both of which have completed Phase I clinical trials[30]. - The company received approvals for 14 generic drugs and 1 active pharmaceutical ingredient during the reporting period, indicating progress in its product pipeline[33]. - The company is focusing on integrating raw materials and formulations to drive new growth, leveraging capacity expansion and process upgrades[23]. Marketing and Sales Strategy - The company is exploring multi-channel marketing strategies to adapt to the changing pharmaceutical supply chain landscape[23]. - The company aims to enhance its competitive advantage by optimizing resource allocation and transforming marketing models in response to centralized procurement policies[24]. - The company is committed to digital marketing strategies to enhance the promotion of slow disease products, ensuring a competitive edge in the market[24]. - The company has established a nationwide sales network with over 2,000 commercial clients, covering more than 150,000 medical terminals and over 200,000 pharmacies[29]. Environmental Compliance - The company reported a total nitrogen emission concentration of 8.59 mg/L, which is below the standard limit of 40 mg/L[56]. - The COD emission concentration was recorded at 110 mg/L, significantly lower than the standard limit of 450 mg/L[56]. - The company achieved a BOD-5 emission concentration of 3.5 mg/L, well within the standard limit of 240 mg/L[56]. - The company has established a comprehensive emergency response plan for sudden environmental incidents across all key pollutant discharge units[60]. - The company conducts regular monitoring of pollutants, including monthly monitoring of boiler emissions and wastewater, ensuring compliance with environmental standards[61]. Corporate Governance and Compliance - The company reported no significant non-operating fund occupation by controlling shareholders or related parties[6]. - There were no violations of decision-making procedures regarding external guarantees during the reporting period[6]. - The company has initiated a compliance management project to strengthen its compliance framework, with a sales expense ratio of approximately 25%[30]. - The company has committed to avoiding and reducing related party transactions after the completion of the major asset restructuring, ensuring compliance with relevant laws and regulations[72]. Financial Management and Investments - The company has invested approximately ¥45.8 million in the construction of its R&D center, with a total investment of about ¥185 million to date[36]. - The company is committed to a low-cost strategy, with a 1% decrease in marketing expense ratio year-on-year, enhancing operational efficiency[29]. - The company has engaged in structured deposits with various banks, including CNY 200 million with China Bank and CNY 280 million with China Bank, with annualized returns ranging from 1.4% to 3.3%[44]. - The total amount of entrusted financial management reached CNY 1.4 billion, with actual returns of CNY 4,985,643.84[45]. Community Engagement - The company has conducted 30 hypertension awareness clinics, benefiting over 600 individuals, as part of its community health initiatives[68]. - The "Heming Action" has completed nearly 3,000 activities, covering 87,000 individuals, focusing on enhancing grassroots medical capabilities[68]. - The company has launched the "Rainbow Plan" 3.0, which includes 188 academic support activities benefiting nearly 3,000 grassroots neonatal doctors across 23 provinces[68]. Shareholder Information - The total number of shares decreased by 27,500, resulting in a total of 1,043,126,810 shares after the change[83]. - The largest shareholder, Beijing Pharmaceutical Group Co., Ltd., holds 625,795,624 shares, accounting for 59.99% of total shares[87]. - The company did not distribute profits or increase capital reserves in the current period, with no dividends or stock bonuses declared[50]. - The total owner's equity at the end of the first half of 2023 is approximately 11.24 billion RMB, an increase from the previous year's 10.48 billion RMB[112].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 证券代码：600062 证券简称：华润双鹤 公告编号：临 2023－054 华润双鹤药业股份有限公司 关于召开 2023 年中期业绩说明会的公告 会议召开时间：2023 年 8 月 29 日(星期二)下午 15:00-16:30 会议召开地点： 现场：北京市朝阳区望京利泽东二路 1 号公司会议室 网络： 上 海 证 券 交 易 所 上 证 路 演 中 心 网 络 平 台 ( 网址： http://roadshow.sseinfo.com/) 会议召开方式：现场、视频结合网络互动 投资者可于 2023 年 8 月 22 日(星期二)至 8 月 28 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱 mss@dcpc.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 华润双鹤药业股份有限公司(以下简称"公司")拟于 2023 年 8 月 24 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2023－053 华润双鹤药业股份有限公司 关于全资子公司双鹤药业(海南)有限责任公司 注射用兰索拉唑通过仿制药质量和疗效一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司全资子公司双鹤药业(海南)有 限责任公司(以下简称"海南双鹤")收到了国家药品监督管理局(以下 简称"国家药监局")颁发的注射用兰索拉唑(以下简称"该药品")《药 品补充申请批准通知书》(通知书编号：2023B02191)，该药品通过仿 制药质量和疗效一致性评价(以下简称"一致性评价")。现将相关情 况公告如下： | 药品名称 | 药品通用名称：注射用兰索拉唑 | | --- | --- | | | 英文名/拉丁名：Lansoprazole for Injection | | 剂型 | 注射剂 | | 注册分类 | 化学药品 | | 规格 | 30mg | | 药品注册标准编号 | YBH07052023 | | 申请内容 | 申请进行仿制药质量和疗效一 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 2,738,700,207.28, representing an increase of 8.76% compared to the same period last year [6] - The net profit attributable to shareholders of the listed company was CNY 372,438,512.01, reflecting a growth of 12.19% year-on-year [6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 359,857,834.38, up by 13.26% from the previous year [6] - Basic earnings per share were CNY 0.3648, an increase of 14.63% compared to the same period last year [6] - Net profit for Q1 2023 was CNY 380,611,022.70, representing a 10.19% increase from CNY 345,356,206.23 in Q1 2022 [19] - The company reported a total profit of CNY 459,686,494.62 for Q1 2023, up from CNY 419,487,247.31 in Q1 2022, an increase of 9.99% [19] Cash Flow - The net cash flow from operating activities decreased by 35.13%, amounting to CNY 116,522,893.59 [6] - The decrease in net cash flow from operating activities was primarily due to increased tax payments and year-end bonuses paid to employees [8] - In Q1 2023, the cash inflow from operating activities was approximately CNY 2.42 billion, an increase of 7.7% compared to CNY 2.25 billion in Q1 2022 [20] - The net cash outflow from operating activities was CNY 116.52 million, down 35.1% from CNY 179.64 million in the same period last year [20] - Cash inflow from investment activities totaled CNY 202.59 million, a decrease of 69.1% from CNY 656.37 million in Q1 2022 [21] - The net cash outflow from investment activities was CNY 439.09 million, worsening from a net outflow of CNY 143.02 million in the previous year [21] - The cash outflow from financing activities was CNY 9.96 million, significantly reduced from CNY 287.51 million in Q1 2022 [21] - The net increase in cash and cash equivalents was a decrease of CNY 333.82 million, compared to a decrease of CNY 118.01 million in the same quarter last year [21] - The ending balance of cash and cash equivalents was CNY 2.28 billion, up from CNY 1.77 billion at the end of Q1 2022 [21] - The company received CNY 2.39 billion in cash from sales and services, an increase from CNY 2.19 billion in the previous year [20] - The total cash outflow for operating activities was CNY 2.30 billion, compared to CNY 2.07 billion in Q1 2022, reflecting a 11.5% increase [20] - The cash received from tax refunds was CNY 17.38 million, down from CNY 22.17 million in Q1 2022 [20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 14,754,931,255.58, which is a 1.88% increase from the end of the previous year [6] - The total assets amounted to CNY 14,754,931,255.58, compared to CNY 14,482,536,656.83 at the end of 2022 [15] - Current assets totaled CNY 7,442,019,261.79, an increase from CNY 7,164,960,901.69 at the end of 2022 [14] - Current liabilities decreased to CNY 2,883,877,993.54 from CNY 3,011,827,593.76 [15] - The total liabilities decreased to CNY 3,636,940,831.93 as of March 31, 2023, from CNY 3,752,890,948.05 at the end of 2022, a reduction of 3.09% [16] - Total equity increased to CNY 11,117,990,423.65 as of March 31, 2023, compared to CNY 10,729,645,708.78 at the end of 2022, reflecting a growth of 3.62% [16] - The equity attributable to shareholders of the listed company was CNY 10,408,710,264.30, reflecting a growth of 3.85% year-on-year [6] Investment and Financial Management - The total amount of entrusted financial management reached CNY 600 million, with an actual return of CNY 1,658,520.55 [12] - The company plans to continue its entrusted financial management strategy, indicating future financial activities [12] - The annualized return rates for entrusted financial products ranged from 1.3% to 3.3% [12] - The company’s investment income for Q1 2023 was CNY 3,896,620.38, significantly higher than CNY 87,593.21 in Q1 2022, indicating a substantial increase [17] Research and Development - Research and development expenses increased to CNY 109,634,519.50 in Q1 2023, up from CNY 83,532,252.23 in Q1 2022, marking a rise of 31.23% [17]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2023－025 华润双鹤药业股份有限公司 关于召开 2023 年一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 9 日(星期二)下午 15:00—16:30 会议召开地点：北京市朝阳区望京利泽东二路 1 号公司会议室 会议召开方式：现场方式 投资者可于 5 月 8 日(星期一)16:00 时前通过公司邮箱 mss@dcpc.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 华润双鹤药业股份有限公司(以下简称"公司")拟于 2023 年 4 月 28 日发布公司 2023 年第一季度报告，为便于广大投资者更全面深入 地了解公司 2023 年一季度经营成果、财务状况，公司计划于 2023 年 5 月 9 日(星期二)下午 15:00—16:30 时举行 2023 年一季度业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以现场方式召开，公司将针对 20 ...